Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Results from a Phase 1 Study and Expanded Cohort of an Interrupted Dosing Schedule of the Aurora Kinase a Inhibitor MLN8237 Combined with Vorinostat in Lymphoid Malignancies

Tanya Siddiqi, MD, Anna Scuto, PhD, Jan H. Beumer, PharmD, PhD, Joo Y. Song, MD, Paul Frankel, PhD, Chris Ruel, MS, Jacob Cobb, BS, Brian F. Kiesel, BS, Dennis D. Weisenburger, MD, Kevin R. Kelly, MD PhD, Joseph Tuscano, MD, Leslie Popplewell, MD, Stephen J. Forman, MD, Richard Piekarz, PhD MD, Edward M. Newman, PhD

Blood (2015) 126 (23): 2731.

https://doi.org/10.1182/blood.V126.23.2731.2731

Published: 2015

Journal Articles

Cyclin D1 Promotes Survival and Chemoresistance By Maintaining ATR and CHEK1 Signaling in TP53-Deficient Mantle Cell Lymphoma Cell Lines

Suchismita Mohanty, PhD, Thai Tran, Natalie Sandoval, Atish Mohanty, PhD, Victoria Bedell, Jun Wu, PhD, Charles Warden, MA, Anna Scuto, PhD, Joyce Collins, PhD, Dennis D. Weisenburger, MD, Vu N. Ngo, PhD

Blood (2014) 124 (21): 5197.

https://doi.org/10.1182/blood.V124.21.5197.5197

Published: 2014

Journal Articles

Cyclin D1 Maintains Mantle Cell Lymphoma Through CDK4-Independent Regulation Of DNA Replicative Checkpoints

Suchismita Mohanty, PhD, Atish Mohanty, PhD, Natalie Sandoval, MS, Victoria Bedell, Joyce Murata-Collins, PhD, Jun Wu, PhD, Anna Scuto, Dennis D. Weisenburger, MD, Vu N Ngo, PhD

Blood (2013) 122 (21): 2512.

https://doi.org/10.1182/blood.V122.21.2512.2512

Published: 2013

Journal Articles

S1PR1 is an effective target to block STAT3 signaling in activated B cell–like diffuse large B-cell lymphoma

Yong Liu, Jiehui Deng, Lin Wang, Heehyoung Lee, Brian Armstrong, Anna Scuto, Claudia Kowolik, Lawrence M. Weiss, Stephen Forman, Hua Yu

Blood (2012) 120 (7): 1458–1465.

https://doi.org/10.1182/blood-2011-12-399030

Published: 2012

Includes: Supplemental data

Journal Articles

Combination Therapy with the Histone Deacetylase Inhibitor Vorinostat Plus the Novel Aurora Kinase A Inhibitor MK-5108 Leads to Enhanced Lymphoma Cell Death Due to Acetylation of p53 and Repression of c-Myc, hTERT, and miRNA Levels.

Leo Kretzner, Anna Scuto, Kowolik Claudia, Richard Jove, Stephen J Forman, MD, Yun Yen, MD, PhD, Mark Kirschbaum, MD

Blood (2009) 114 (22): 1690.

https://doi.org/10.1182/blood.V114.22.1690.1690

Published: 2009

Journal Articles

Novel SIRT1 Agonists, SRT501 and SRT2183, Induce Expression of DNA Repair Genes and Apoptosis of Ph − Acute Lymphoblastic Leukemia Cells Alone and in Combination with the HDAC Inhibitor LBH589..

Anna Scuto, Mark Kirschbaum, MD, Jennifer M Cermak, Peter Atadja, Richard Jove

Blood (2009) 114 (22): 3083.

https://doi.org/10.1182/blood.V114.22.3083.3083

Published: 2009

Journal Articles

STAT3 Silencing as a Novel Therapeutic Strategy for Activated B Cell-Type Diffuse Large B-Cell Lymphoma.

Anna Scuto, Maciej Kujawski, Claudia Kowolik, Hua Yu, Stephen Forman, Richard Jove

Blood (2009) 114 (22): 926.

https://doi.org/10.1182/blood.V114.22.926.926

Published: 2009

Journal Articles

Combination Therapy with Histone Deacetylase Inhibitor Vorinostat Plus Aurora Kinase Inhibitor MK-0457 Leads to Enhanced Lymphoma Cell Killing with Stabilization of p53 and Repression of C-Myc, hTERT, and Myc-Responsive miRNAs

Leo Kretzner, Anna Scuto, Richard Jove, Stephen J. Forman, MD, Yun Yen, MD, PhD, Mark Kirschbaum, MD

Blood (2008) 112 (11): 3628.

https://doi.org/10.1182/blood.V112.11.3628.3628

Published: 2008

Journal Articles

The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph − acute lymphoblastic leukemia cells

Anna Scuto, Mark Kirschbaum, Claudia Kowolik, Leo Kretzner, Agnes Juhasz, Peter Atadja, Vinod Pullarkat, Ravi Bhatia, Stephen Forman, Yun Yen, Richard Jove

Blood (2008) 111 (10): 5093–5100.

https://doi.org/10.1182/blood-2007-10-117762

Published: 2008

Includes: Supplemental data

Journal Articles

Combination of the Histone Deacetylase Inhibitor Vorinostat and Dasatinib Increases Apoptosis in Bcr-abl+ Cells and Reverses Changes Associated with CML Progression.

Leo Kretzner, PhD, Anna Scuto, PhD, Agnes Juhasz, PhD, Richard Jove, PhD, Yun Yen, MD, Stephen J. Forman, MD, Mark Kirschbaum

Blood (2006) 108 (11): 2165.

https://doi.org/10.1182/blood.V108.11.2165.2165

Published: 2006

Journal Articles

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3

Prince George, Purva Bali, Srinivas Annavarapu, Anna Scuto, Warren Fiskus, Fei Guo, Celia Sigua, Gautam Sondarva, Lynn Moscinski, Peter Atadja, Kapil Bhalla

Blood (2005) 105 (4): 1768–1776.

https://doi.org/10.1182/blood-2004-09-3413

Published: 2005

Journal Articles

Mechanistic role of heat shock protein 70 in Bcr-Abl–mediated resistance to apoptosis in human acute leukemia cells

Fei Guo, Celia Sigua, Purva Bali, Prince George, Warren Fiskus, Anna Scuto, Srinivas Annavarapu, Abdelmoughite Mouttaki, Gautam Sondarva, Sheng Wei, Jie Wu, Julie Djeu, Kapil Bhalla

Blood (2005) 105 (3): 1246–1255.

https://doi.org/10.1182/blood-2004-05-2041

Published: 2005

Journal Articles

Synergistic Cytotoxic Effects of a Combination of a Novel Tyrosine Kinase Inhibitor AMN107 and Histone Deacetylase Inhibitor LBH589 Against Bcr-Abl Expressing Human Leukemia Cells.

Anna Scuto, Ph.D., Srinivas Annavarapu, M.S., Purva Bali, M.S., Molly McCullers, Warren Fiskus, Ph.D., Abdelmoughite Mouttaki, B.S., Fei Guo, Ph.D., Celia Sigua, M.S., Gautam Sondarva, Ph.D., Peter Atadja, Ph.D., Paul Manley, Ph.D., Kapil N. Bhalla, M.D.

Blood (2004) 104 (11): 1977.

https://doi.org/10.1182/blood.V104.11.1977.1977

Published: 2004

NARROW

Results from a Phase 1 Study and Expanded Cohort of an Interrupted Dosing Schedule of the Aurora Kinase a Inhibitor MLN8237 Combined with Vorinostat in Lymphoid Malignancies

Cyclin D1 Promotes Survival and Chemoresistance By Maintaining ATR and CHEK1 Signaling in TP53-Deficient Mantle Cell Lymphoma Cell Lines

Cyclin D1 Maintains Mantle Cell Lymphoma Through CDK4-Independent Regulation Of DNA Replicative Checkpoints

S1PR1 is an effective target to block STAT3 signaling in activated B cell–like diffuse large B-cell lymphoma

Combination Therapy with the Histone Deacetylase Inhibitor Vorinostat Plus the Novel Aurora Kinase A Inhibitor MK-5108 Leads to Enhanced Lymphoma Cell Death Due to Acetylation of p53 and Repression of c-Myc, hTERT, and miRNA Levels.

Novel SIRT1 Agonists, SRT501 and SRT2183, Induce Expression of DNA Repair Genes and Apoptosis of Ph − Acute Lymphoblastic Leukemia Cells Alone and in Combination with the HDAC Inhibitor LBH589..

STAT3 Silencing as a Novel Therapeutic Strategy for Activated B Cell-Type Diffuse Large B-Cell Lymphoma.

Combination Therapy with Histone Deacetylase Inhibitor Vorinostat Plus Aurora Kinase Inhibitor MK-0457 Leads to Enhanced Lymphoma Cell Killing with Stabilization of p53 and Repression of C-Myc, hTERT, and Myc-Responsive miRNAs

The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph − acute lymphoblastic leukemia cells

Combination of the Histone Deacetylase Inhibitor Vorinostat and Dasatinib Increases Apoptosis in Bcr-abl+ Cells and Reverses Changes Associated with CML Progression.

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3

Mechanistic role of heat shock protein 70 in Bcr-Abl–mediated resistance to apoptosis in human acute leukemia cells

Synergistic Cytotoxic Effects of a Combination of a Novel Tyrosine Kinase Inhibitor AMN107 and Histone Deacetylase Inhibitor LBH589 Against Bcr-Abl Expressing Human Leukemia Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only